Mesoblast (MEOBF) Non-Current Assets (2014 - 2026)
Mesoblast's (MEOBF) quarterly Non-Current Assets came in at $575.6 million in Q2 2026, down 0.82% year-over-year from $580.3 million in Q2 2025, and down 0.73% quarter-over-quarter from $579.8 million in Q4 2025.
Analysis
Mesoblast (MEOBF) Non-Current Assets (2014 - 2026) Analysis & Trends
Mesoblast has disclosed Non-Current Assets across 13 years of filings, most recently posting $575.6 million for Q2 2026.
- In Q2 2026, Non-Current Assets fell 0.82% year-over-year to $575.6 million; the TTM figure through Jun 2026 stood at $575.6 million (down 0.82% YoY), while the FY2026 annual figure was $575.6 million, down 0.82% from the prior year.
- Non-Current Assets came in at $575.6 million for Q2 2026 at Mesoblast, down from $579.8 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $593.6 million in Q1 2022 to a low of $575.6 million in Q2 2026.
- Average Non-Current Assets over 5 years is $585.9 million, with a median of $586.4 million recorded in 2023.
- Year-over-year, Non-Current Assets retreated 0.96% in 2022 and decreased 0.25% in 2024.
- Over 5 years, Non-Current Assets stood at $589.9 million in 2022, then dropped by 0.81% to $585.1 million in 2023, then decreased by 0.25% to $583.6 million in 2024, then slipped by 0.65% to $579.8 million in 2025, then decreased by 0.73% to $575.6 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $575.6 million in Q2 2026, $579.8 million in Q4 2025, and $580.3 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.27 Bn | 9.43 Bn | 112.79 Mn | 441.00 Mn |
| 2 | CRISPR Therapeutics AG | 5.17 Bn | 5.17 Bn | - | 279.00 Mn |
| 3 | Iovance Biotherapeutics | 3.79 Bn | 3.49 Bn | 55.72 Mn | 451.27 Mn |
| 4 | Legend Biotech | 3.68 Bn | 2.71 Bn | 251.50 Mn | 523.50 Mn |
| 5 | uniQure | 3.05 Bn | 3.05 Bn | 5.49 Mn | 150.83 Mn |
| 6 | Beam Therapeutics | 2.65 Bn | 2.65 Bn | - | 207.76 Mn |
| 7 | Precigen | 2.44 Bn | 2.44 Bn | 52.17 Mn | 35.91 Mn |
| 8 | Sarepta Therapeutics | 2.33 Bn | 1.53 Bn | 251.87 Mn | 964.69 Mn |
| 9 | Vericel | 1.99 Bn | 1.83 Bn | 56.40 Mn | 238.14 Mn |
| 10 | Mesoblast | 246.02 Mn | 143.11 Mn | - | 575.59 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 575.59 Mn |
| Dec 31, 2025 | 579.82 Mn |
| Jun 30, 2025 | 580.33 Mn |
| Dec 31, 2024 | 583.64 Mn |
| Jun 30, 2024 | 582.69 Mn |
| Dec 31, 2023 | 585.13 Mn |
| Jun 30, 2023 | 587.76 Mn |
| Mar 31, 2023 | 589.08 Mn |
| Dec 31, 2022 | 589.93 Mn |
| Sep 30, 2022 | 591.54 Mn |
| Jun 30, 2022 | 592.31 Mn |
| Mar 31, 2022 | 593.56 Mn |
| Dec 31, 2021 | 595.64 Mn |
| Sep 30, 2021 | 595.60 Mn |
| Jun 30, 2021 | 596.49 Mn |
| Mar 31, 2021 | 596.36 Mn |
| Dec 31, 2020 | 596.85 Mn |
| Sep 30, 2020 | 596.84 Mn |
| Jun 30, 2020 | 597.05 Mn |
| Mar 31, 2020 | 596.40 Mn |